Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782548 · ClinicalTrials.gov registry record · Phase 4
Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults
A Phase 4 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00782548 is a Phase 4 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT00782548, a Phase 4 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations
Interventions
- DRUG KADIAN (morphine sulfate sustained-release) capsules
- DRUG Avinza (morphine sulfate sustained-release) capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782548
The ClinicalTrials.gov registry entry for NCT00782548 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KADIAN (morphine sulfate sustained-release) capsules is the first listed.
NCT00782548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782548 about?
NCT00782548 is a clinical study titled "Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults". The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary ob...
What is the current status of trial NCT00782548?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2004-05. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00782548?
The interventions under investigation include: KADIAN (morphine sulfate sustained-release) capsules (DRUG), Avinza (morphine sulfate sustained-release) capsules (DRUG).
Who is sponsoring clinical trial NCT00782548?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.